openPR Logo
Press release

Pemphigus Vulgaris Treatment Market Insights Focusing on Primary Trends until 2028 // F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, GlaxoSmithClaine, Syntimmune, Argenx, Principia Biopharma, HanAll Biopharma

05-22-2019 09:50 AM CET | Industry, Real Estate & Construction

Press release from: Fact.MR

Pemphigus Vulgaris Treatment Market Insights Focusing

The increasing demand for biological therapies for pemphigus vulgaris treatment is because of their less side effects. Whereas, glucocorticoids can lead to several drug-related reactions. The growing demand for Mabs is expected to drive the growth of the pemphigus vulgaris treatment market during the forecast period. As there are less options available in market for pemphigus vulgaris treatment, and various side effects of marketed non-biological drugs, boost up the research for Pemphigus Vulgaris Treatment and its market. However, high cost of biological drugs and its availability are the major factors expected to hinder the growth of the Pemphigus Vulgaris Treatment Market. 

Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=2185

Pemphigus vulgaris (PV) is a rare auto-immune disorder with less treatment options. It causes painful blisters on the mucous membrane of the eye, genitals, mouth, throat, nose or skin. Pemphigus vulgaris does not depends on age of a person, it can affect anybody. Pemphigus vulgaris mainly develops due to adverse drug reaction (ADR) of drugs such as enalapril, captopril, penicillamine, some antibiotics, etc. Based on the severity of symptoms, sometimes the patients need to be hospitalized as the disease is life-threatening. Several drugs for the treatment of pemphigus vulgaris such as Corticosteroids and Immunosuppressant are available worldwide. Nowadays, biological treatment such as Rituximab is considered as new approach for pemphigus vulgaris treatment. Most of the randomized, controlled clinical studies have proved Rituximab as a first-line drug for pemphigus vulgaris treatment. In 2017, the FDA approved “Breakthrough Designation” status to MabThera (F. Hoffmann-La Roche Ltd) for pemphigus vulgaris treatment. The objective of pemphigus vulgaris treatment is to reduce blister formation, initiate healing of the erosions and reduce dose of medications to the lowest possible dose. There is no particular cure for pemphigus vulgaris, but pemphigus vulgaris treatment can help prevent the aggravation of the symptoms. 

Pemphigus Vulgaris Treatment Market: Overview

The global market for pemphigus vulgaris treatment is expected to witness significant growth over the forecast period due to high demand for biological therapies for pemphigus vulgaris treatment. By RoA, the subcutaneous drug delivery segment is expected to experience high demand, as it delivers the drug directly to the blood stream resulting in less side effects. Among various indications of pemphigus vulgaris treatment, is expected to gain attraction over the forecast period, primarily due to growing prevalence of Pemphigus Vulgaris (PV). Some of the popular brands of Pemphigus Vulgaris Treatment market include MabThera (F. Hoffmann-La Roche Ltd), Prednisone (Sanofi) etc.

To know more about the Pemphigus Vulgaris Treatment Market Visit the link- https://www.factmr.com/report/2185/pemphigus-vulgaris-treatment-market

Pemphigus Vulgaris Treatment: Regional Outlook

Geographically, the global pemphigus vulgaris treatment market is segmented into North America, Latin America, Europe, CIS & Russia, Asia-Pacific Excluding Japan, Japan and the Middle East & Africa. North America is expected to be the dominant regional market for pemphigus vulgaris treatment on account of growing research and development for novel pemphigus vulgaris treatment along with advancements in the healthcare sector. The Europe pemphigus vulgaris treatment market is expected to account second large revenue share in the global pemphigus vulgaris treatment market over the forecast period owing to increasing prevalence of pemphigus vulgaris in the region. Fast growth is expected in the Asia-Pacific market, due to technological advancement in the health care sector and increasing investment in life-science research.

Pemphigus Vulgaris Treatment: Key Players 

The global pemphigus vulgaris treatment market is highly fragmented with a large number of global players operating. Examples of some of the key players operating in the global pemphigus vulgaris treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, GlaxoSmithClaine, Syntimmune, Argenx, Principia Biopharma, and HanAll Biopharma, among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=2185

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - http://westminsternewsonline.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pemphigus Vulgaris Treatment Market Insights Focusing on Primary Trends until 2028 // F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, GlaxoSmithClaine, Syntimmune, Argenx, Principia Biopharma, HanAll Biopharma here

News-ID: 1748696 • Views:

More Releases from Fact.MR

Demand for Dry Powder Inhalers is forecasted to reach a market value of US$ 2.2 billion by 2034
Demand for Dry Powder Inhalers is forecasted to reach a market value of US$ 2.2 …
The global dry powder inhaler (DPI) market is estimated to be worth US$ 1.1 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% to reach a valuation of US$ 2.2 billion by the end of 2034, according to a comprehensive study conducted by Fact.MR. Download Sample Copy of This Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=7083 The demand for dry powder inhalers is expected to rise due to the
Global ISO Certification Market is projected to expand at a CAGR of 15.2% from 2024 to 2034
Global ISO Certification Market is projected to expand at a CAGR of 15.2% from 2 …
According to a recently released Fact.MR analysis, the global market for ISO certification is expected to be valued at US$ 16.14 billion by 2024. By the end of 2034, revenue from ISO certification is expected to grow at a 15.2% compound annual growth rate and reach a market valuation of US$ 66.25 billion. In order to prove compliance with environmental, quality, or information security rules, a variety of sectors require ISO
Gluten-free Bakery Products Market is expected to grow at a CAGR of 9.8% from 2024-2034
04-25-2024 | Food & Beverage
Fact.MR
Gluten-free Bakery Products Market is expected to grow at a CAGR of 9.8% from 20 …
The gluten-free bakery products market is a dynamic sector influenced by various factors such as consumer dietary preferences, health trends, and advancements in food technology. As awareness of celiac disease and gluten sensitivities grows, so does the demand for gluten-free alternatives in baked goods. Download Sample Copy of This Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=3035 Gluten is a protein fraction generated from wheat, rye, barley, oats, and their derivatives and hybrids. It is an essential part
Pet Grooming Services Market is projected to expand at a CAGR of 7.2% from 2024 to 2034
Pet Grooming Services Market is projected to expand at a CAGR of 7.2% from 2024 …
The global pet grooming services market is anticipated to rise at a compound annual growth rate (CAGR) of 7.2%, from a value of US$ 3.3 billion in 2024 to US$ 6.7 billion by the end of 2034, according to the most recent market research analysis published by Fact.MR. Pets are now considered members of the family by many. Pet owners want the best for their furry pals, just as much as

All 5 Releases


More Releases for Pemphigus

Pemphigus Vulgaris Treatment is Emerging Economies with Principia Biopharma, Arg …
Global Pemphigus Vulgaris Treatment Market Report 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Pemphigus Vulgaris Treatment Market. Some of the key players profiled in the study are Principia Biopharma, Argenx SE, Alexion
Global Pemphigus Vulgaris Market Research Report Forecast to 2027
Pemphigus Vulgaris Market 2020 comprises a detailed survey of the Pemphigus Vulgaris Market size, share, trends, extension, consumption, and share, segments, application and Forecast 2025. Global "Pemphigus Vulgaris" Market 2020-2025 Report contains all demographic as well as analytical data regarding market review, growth, demand, and budget analysis. The report mainly highlights the significant trends of the Pemphigus Vulgaris market in terms of thriving companies, business methods, product values and pricing, revenue,
Pemphigus Vulgaris Treatment Market Research 2020 by Industry Size, Trends and F …
The authors of the report have deeply researched about key areas of the global Pemphigus Vulgaris Treatment market and provided verified market findings and reliable recommendations to help players ensure long-term growth. The report on the global Pemphigus Vulgaris Treatment market is just the resource that players need to strengthen their overall growth and establish a strong position in their business. It is a compilation of detailed, accurate research studies that
Pemphigus Vulgaris Treatment Market Shares, Strategies and Forecast Worldwide, 2 …
Pemphigus vulgaris (PV) is a rare auto-immune disorder with less treatment options. It causes painful blisters on the mucous membrane of the eye, genitals, mouth, throat, nose or skin. Pemphigus vulgaris does not depends on age of a person, it can affect anybody. Pemphigus vulgaris mainly develops due to adverse drug reaction (ADR) of drugs such as enalapril, captopril, penicillamine, some antibiotics, etc. Based on the severity of symptoms, sometimes
Growing Global Prevalence of Cancer and Increasing Consumption of Tobacco Drive …
Paraneoplastic pemphigus is an autoimmune disease characterized by the formation of blisters that affect the mucous membranes and / or skin. It falls under the “rare diseases” category and can affect both males and females. According to Ophanet, paraneoplastic pemphigus affects 1 in 2,000 people. It is a rare form of pemphigus usually associated with lymph proliferative disorders such as Castleman disease, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma. Paraneoplastic
Paraneoplastic Pemphigus (PNP) Disease Market Forecast Research Reports Offers K …
Paraneoplastic pemphigus is an autoimmune disease characterized by the formation of blisters that affect the mucous membranes and / or skin. It falls under the “rare diseases” category and can affect both males and females. According to Ophanet, paraneoplastic pemphigus affects 1 in 2,000 people. It is a rare form of pemphigus usually associated with lymph proliferative disorders such as Castleman disease, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma. Paraneoplastic